blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3543238

EP3543238 - NUCLEOSIDE DERIVATIVES HAVING ANTI-VIRAL ACTIVITY [Right-click to bookmark this link]
Former [2019/39]NUCLEOSIDE DERIVATIVE HAVING PHYSICAL ACTIVITIES INCLUDING ANTI-VIRAL ACTIVITY
[2021/07]
StatusNo opposition filed within time limit
Status updated on  25.03.2022
Database last updated on 13.09.2024
FormerThe patent has been granted
Status updated on  16.04.2021
FormerGrant of patent is intended
Status updated on  11.02.2021
FormerRequest for examination was made
Status updated on  23.08.2019
FormerThe international publication has been made
Status updated on  25.05.2018
Most recent event   Tooltip13.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 16.10.2024 [2024/42]
Applicant(s)For all designated states
National Center for Global Health and Medicine
1-21-1, Toyama Shinjuku-ku
Tokyo 162-8655 / JP
[2019/39]
Inventor(s)01 / MITSUYA Hiroaki
c/o National Center for Global Health and Medicine
1-21-1 Toyama
Shinjuku-ku
Tokyo 162-8655 / JP
02 / KUMAMOTO Hiroki
c/o National Center for Global Health and Medicine
1-21-1 Toyama
Shinjuku-ku
Tokyo 162-8655 / JP
 [2019/39]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[N/P]
Former [2021/20]J A Kemp LLP
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Former [2019/39]J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date17871309.513.11.2017
[2019/39]
WO2017JP40790
Priority number, dateJP2016022351116.11.2016         Original published format: JP 2016223511
[2019/39]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018092728
Date:24.05.2018
Language:JA
[2018/21]
Type: A1 Application with search report 
No.:EP3543238
Date:25.09.2019
Language:EN
[2019/39]
Type: B1 Patent specification 
No.:EP3543238
Date:19.05.2021
Language:EN
[2021/20]
Search report(s)International search report - published on:JP24.05.2018
(Supplementary) European search report - dispatched on:EP16.06.2020
ClassificationIPC:C07D473/18, A61P31/12, A61P31/18, A61P31/20, A61K31/522, A61K45/06
[2020/29]
CPC:
A61K31/522 (EP,US); A61K45/06 (EP); A61P31/12 (EP,US);
A61P31/18 (EP,US); A61P31/20 (EP,US); C07D473/18 (EP);
C07D487/04 (US) (-)
Former IPC [2019/39]C07D487/04, A61K31/522, A61P31/12, A61P31/18, A61P31/20
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/39]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:NUKLEOSIDDERIVATE MIT ANTIVIRALER AKTIVITÄT[2021/07]
English:NUCLEOSIDE DERIVATIVES HAVING ANTI-VIRAL ACTIVITY[2021/07]
French:DÉRIVÉS NUCLÉOSIDIQUES AYANT UNE ACTIVITÉ ANTIVIRALE[2021/07]
Former [2019/39]NUKLEOSIDDERIVAT MIT PHYSISCHEN AKTIVITÄTEN MIT ANTIVIRALER AKTIVITÄT
Former [2019/39]NUCLEOSIDE DERIVATIVE HAVING PHYSICAL ACTIVITIES INCLUDING ANTI-VIRAL ACTIVITY
Former [2019/39]DÉRIVÉ NUCLÉOSIDIQUE AYANT DES ACTIVITÉS PHYSIQUES COMPRENANT UNE ACTIVITÉ ANTIVIRALE
Entry into regional phase24.05.2019Translation filed 
24.05.2019National basic fee paid 
24.05.2019Search fee paid 
24.05.2019Designation fee(s) paid 
24.05.2019Examination fee paid 
Examination procedure13.09.2018Request for preliminary examination filed
International Preliminary Examining Authority: JP
24.05.2019Examination requested  [2019/39]
07.12.2020Amendment by applicant (claims and/or description)
12.02.2021Communication of intention to grant the patent
12.04.2021Fee for grant paid
12.04.2021Fee for publishing/printing paid
12.04.2021Receipt of the translation of the claim(s)
Opposition(s)22.02.2022No opposition filed within time limit [2022/17]
Fees paidRenewal fee
26.11.2019Renewal fee patent year 03
20.11.2020Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU13.11.2017
AL19.05.2021
AT19.05.2021
CY19.05.2021
CZ19.05.2021
DK19.05.2021
EE19.05.2021
ES19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
MK19.05.2021
MT19.05.2021
NL19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SE19.05.2021
SI19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
LU13.11.2021
[2024/42]
Former [2024/23]HU13.11.2017
AL19.05.2021
AT19.05.2021
CY19.05.2021
CZ19.05.2021
DK19.05.2021
EE19.05.2021
ES19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
MK19.05.2021
NL19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SE19.05.2021
SI19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
LU13.11.2021
Former [2023/33]HU13.11.2017
AL19.05.2021
AT19.05.2021
CY19.05.2021
CZ19.05.2021
DK19.05.2021
EE19.05.2021
ES19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
NL19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SE19.05.2021
SI19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
LU13.11.2021
Former [2023/30]AL19.05.2021
AT19.05.2021
CY19.05.2021
CZ19.05.2021
DK19.05.2021
EE19.05.2021
ES19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
NL19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SE19.05.2021
SI19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
LU13.11.2021
Former [2022/34]AL19.05.2021
AT19.05.2021
CZ19.05.2021
DK19.05.2021
EE19.05.2021
ES19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
NL19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SE19.05.2021
SI19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
LU13.11.2021
Former [2022/33]AL19.05.2021
AT19.05.2021
CZ19.05.2021
DK19.05.2021
EE19.05.2021
ES19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
NL19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SE19.05.2021
SI19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/29]AL19.05.2021
AT19.05.2021
CZ19.05.2021
DK19.05.2021
EE19.05.2021
ES19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
NL19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SE19.05.2021
SI19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/26]AL19.05.2021
AT19.05.2021
CZ19.05.2021
DK19.05.2021
EE19.05.2021
ES19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
NL19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SE19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/23]AT19.05.2021
CZ19.05.2021
DK19.05.2021
EE19.05.2021
ES19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
NL19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SE19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/10]AT19.05.2021
CZ19.05.2021
DK19.05.2021
EE19.05.2021
ES19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
NL19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SE19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
PT20.09.2021
IS22.12.2021
Former [2022/09]AT19.05.2021
CZ19.05.2021
DK19.05.2021
ES19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
NL19.05.2021
PL19.05.2021
RO19.05.2021
RS19.05.2021
SE19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/08]AT19.05.2021
CZ19.05.2021
DK19.05.2021
ES19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
NL19.05.2021
PL19.05.2021
RS19.05.2021
SE19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/07]AT19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
NL19.05.2021
PL19.05.2021
RS19.05.2021
SE19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/04]AT19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
NL19.05.2021
PL19.05.2021
RS19.05.2021
SE19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2021/52]AT19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
PL19.05.2021
RS19.05.2021
SE19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2021/51]AT19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
RS19.05.2021
SE19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2021/50]AT19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
SE19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
PT20.09.2021
Former [2021/49]AT19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
SE19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
Former [2021/47]AT19.05.2021
FI19.05.2021
LT19.05.2021
BG19.08.2021
Former [2021/46]AT19.05.2021
FI19.05.2021
LT19.05.2021
Documents cited:Search[IA]WO2015077360  (IDENIX PHARMACEUTICALS INC [US]) [I] 1,3-15 * abstract * * page 45; compound 333/a/b/c * * page 47; compound 433/a/b/c * [A] 2;
 [T]  - HIGASHI-KUWATA, N. ET AL., "CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (20190327), vol. 63, no. 4, doi:10.1128/AAC.02143-18, ISSN 0066-4804, pages 1 - 17, XP055667538 [T] 1-15

DOI:   http://dx.doi.org/10.1128/AAC.02143-18
International search[Y]JPH04282373  (BRISTOL MYERS SQUIBB CO) [Y] 1-4 * , & US 5206244 & EP 481754 A2 & KR 10-0160523 B & CN 1061972 A *;
 [Y]JPH0680688  (ASAHI BREWERIES LTD) [Y] 1-4 * , *;
 [Y]JP2011503234  [Y] 1-4 * , & WO 2009/067409 A1, & US 2009/0318380 A1 & EP 2227482 A1 & CN 101932590 A *;
 [Y]JP2013510904  [Y] 1-4 * , *;
 [Y]WO2016134054  (ABBVIE INC [US]) [Y] 1-4 * , *;
 [Y]  - Ohrui, Hiroshi, "Creation of low-toxic high-activity reverse transcriptase-inhibiting nucleosides that do not express resistant HIV. Could it be a magic bullet for AIDS and hepatitis B dreams?]", Kagaku to seibutsu, (20060000), vol. 44, no. 10, pages 660 - 662, XP009514931 [Y] 1-4
 [Y]  - TAKAMATSU, Y. et al., "4′-modified nucleoside analogs: Potent inhibitors active against entecavir-resistant hepatitis B virus", HEPATOLOGY, (20150000), vol. 62, no. 4, doi:10.1002/hep.27962, ISSN 0270-9139, pages 1024 - 1036, XP055605356 [Y] 1-4

DOI:   http://dx.doi.org/10.1002/hep.27962
 [Y]  - KODAMA, E., "4'-Ethynyl Nucleoside Analogs: Potent Inhibitors of Multidrug-Resistant Human Immunodeficiency Virus Variants In Vitro", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (20010000), vol. 45, no. 5, doi:10.1128/AAC.45.5.1539-1546.2001, ISSN 0066-4804, pages 1539 - 1546, XP001127402 [Y] 1-4 * , *

DOI:   http://dx.doi.org/10.1128/AAC.45.5.1539-1546.2001
 [Y]  - KUMAMOTO, H . et al., "Diastereoselective Synthesis of 6″-( Z )- and 6″-( E )-Fluoro Analogues of Anti-hepatitis B Virus Agent Entecavir and Its Evaluation of the Activity and Toxicity Profile of the Diastereomers", The Journal of Organic Chemistry, (20160324), vol. 81, no. 7, doi:10.1021/acs.joc.6b00105, ISSN 0022-3263, pages 2827 - 2836, XP055605358 [Y] 1-4 * , *

DOI:   http://dx.doi.org/10.1021/acs.joc.6b00105
by applicantJP2001335592
 JP2001335593
 WO03068796
 JP2004107329
 JP2004244422
 WO2005090349
 JP2008273960
    - J. Org. Chem., (20040000), vol. 69, page 2634
    - J. Org. Chem., (20000000), vol. 65, page 7697
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.